<DOC>
	<DOCNO>NCT02909972</DOCNO>
	<brief_summary>Phase I , open label , multi-center dose escalation ( DEP ) dose expansion ( EXP ) study design evaluate safety , tolerability , PK ( pharmacokinetics ) , PD ( pharmacodynamics ) anti-tumor effect ALRN-6924 patient acute myeloid leukemia advance myelodysplastic syndrome wild-type ( WT ) TP53 .</brief_summary>
	<brief_title>Safety Study ALRN-6924 Patients With Acute Myeloid Leukemia Advanced Myelodysplastic Syndrome</brief_title>
	<detailed_description>Phase I , open label , multi-center dose escalation ( DEP ) dose expansion ( EXP ) study design evaluate safety , tolerability , PK ( pharmacokinetics ) , PD ( pharmacodynamics ) anti-tumor effect ALRN-6924 patient acute myeloid leukemia advance myelodysplastic syndrome wild-type ( WT ) TP53 . ALRN-6924 staple peptide design disrupt integration p53 tumor suppression protein inhibition murine double minute 2 ( MDM2 ) murine double minute X ( MDMX ) . Men woman 18 year age old relapse refractory acute myeloid leukemia advance myelodysplastic syndrome standard treatment ( ) available longer effective enrol . Treatment patient DEP EXP phase continue study documentation disease progression , unacceptable toxicity , patient physician decision discontinue study participation make .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Male female patient age 18 year old , inclusive , time informed consent Relapsed refractory acute myeloid leukemia IPSSR intermediate/high/very highrisk MDS patient Wildtype TP53 status ECOG ( Eastern Cooperative Oncology Group ) performance status 02 Predicted life expectancy ≥3 month Adequate hematologic function Adequate hepatic function Acceptable coagulation profile Recovery significant toxicity previous therapy sufficient time since last dose previous therapy Negative serum urine pregnancy test within 7 day prior first dose ALRN6924 woman childbearing potential Ability understand willingness sign write informed consent document Willing able undergo pre subsequent ontreatment bone marrow biopsies Patients eligible available approve standard therapy Patients myelodysplastic/myeloproliferative neoplasm Previous treatment investigational agent inhibit MDM2 MDMX activity ( MDM2treated patient may eligible ) Patients history allogeneic stem cell transplantation Leukemic blast count &gt; 25,000/µl Deletion chromosome 17 , del ( 17p ) Patients evidence current central nervous system leukemic involvement Known hypersensitivity study drug component History coagulopathy History pulmonary embolism within 6 month prior first dose ALRN6924 untreated DVT ( deep vein thrombosis ) Required concurrent use anticoagulant antiplatelet medication , exception aspirin dose ≤81 mg/day , lowdose SC heparin SC lowmolecularweight heparin DVT prophylaxis , heparin flush maintain IV catheter patency Patients preexist history know cardiovascular risk Clinically significant gastrointestinal bleeding within 6 month prior first dose ALRN6924 Clinically significant thirdspace fluid accumulation Pregnant lactating female Evidence serious and/or unstable preexist medical condition would interfere patient safety ability provide inform consent Active uncontrolled infection , include HIV/AIDS Hepatitis B C Known history another primary malignancy remission ≥1 year Any condition may interfere compliance study protocol Required use medication predominantly clear hepatobiliary transporter within 48 hour study drug infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>